By asianet
Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ … Continued
By asianet
Psoriatic disease is an inflammatory illness that affects the skin and joints. Itchy, flaky patches of skin are perhaps the most common symptom. But psoriatic disease goes far deeper. For many, one of the most difficult challenges in living with psoriatic disease is its heavy impact on mental health. Today, IFPA – the global organization … Continued
By asianet
Healion Bio, a closely held biotechnology company, today announced a collaborative agreement to research a combination antiviral against SARS-CoV-2 and other deadly pathogens. The combination will include one of Healion Bio’s protease inhibitors and Favipiravir (its trade name, Avigan), an antiviral drug developed by FUJIFILM Toyama Co., Ltd., Tokyo, Japan. Logo – https://mma.prnewswire.com/media/1803052/Healion_Bio_Logo.jpg Dr. Sina … Continued
By asianet
– Bringing clinical insights into early product development Varian, a Siemens Healthineers company (Varian), today announced a five-year research and professional services agreement with Icon Group (Icon). Through this agreement, Icon will participate in clinical and technical research programs, product evaluation projects, and clinical consultations with Varian to offer Icon’s clinical expertise and industry perspectives … Continued
By asianet
HealthBeats(TM), a Singapore-based healthtech start-up with end-to-end remote vitals monitoring solution, today announced the close of a US$3m Seed round led by healthcare investor Heritas Capital together with SEEDS Capital, the investment arm of government agency Enterprise Singapore. The HealthBeats(TM) Remote Vitals Monitoring platform provides healthcare providers and patients with a simple-to-use and simple-to-deploy solution … Continued
By asianet
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that the company’s mymobility(R) digital care management platform won “The Care Management Initiative of the Year” award at this year’s Healthcare Asia Medtech Awards. mymobility(R) is a digital care management platform that uses iPhone(R) and Apple Watch(R) or Android devices … Continued
By asianet
Glooko, Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the appointment of Alfonso “Chito” Zulueta to its Board of Directors. Logo – https://mma.prnewswire.com/media/1043398/Glooko_Logo.jpg Respected as a leader with a strong track record of success in the pharmaceutical industry and deep experience on corporate … Continued
By asianet
Direct Biologics ( https://c212.net/c/link/?t=0&l=en&o=3515622-1&h=961943011&u=https%3A%2F%2Fwww.directbiologics.com%2F&a=Direct+Biologics ), a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct Biologics is the first … Continued
By asianet
-Provides Ct value of three targets in one channel; ‘3 Ct’ PCR assay to launch in H1 -“Dream MDx technology” developed based on Seegene’s 20-year expertise; combines 19 different patented technologies, including DPO(TM), TOCE(TM), MuDT(TM)-‘3 Ct’ to lay foundation for automated syndromic testing and make MDx more accessible Seegene Inc. (KQ096530), South Korea’s leading molecular … Continued
By asianet
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol(R) for the treatment of dry eye disease (DED), was presented as part of a podium symposium at the American Cataract … Continued